Thermo Fisher Scientific reported second quarter 2026 financial results for the period ended June 27, 2026. Revenue increased 10% to $11.99 billion, representing 5% organic growth. GAAP diluted earnings per share grew 9% to $4.68, while adjusted EPS rose 13% to $6.03. The company reported GAAP operating income of $2.09 billion and adjusted operating income of $2.73 billion. During the quarter, the company announced the divestiture of its microbiology business and repurchased $1.0 billion of stock. Thermo Fisher Scientific is a global provider of scientific instrumentation, analytical instruments, and laboratory solutions.